Business Context and Reporting Period
This Form 8-K is a current report filed by AlloVir, Inc. (not Kalaris Therapeutics, Inc.) on March 31, 2022, covering events that occurred on March 29, 2022. The company is a Delaware corporation listed on the Nasdaq Global Select Market under the symbol ALVR and is classified as an emerging growth company.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
- Board Appointment: Shawn Tomasello was appointed to the Board of Directors effective March 29, 2022. She serves as a Class III director until the 2023 annual meeting and is deemed independent under Nasdaq listing standards.
- Board Departure: John Wilson notified the Board on March 29, 2022, that he will retire and will not stand for re-election at the 2022 annual meeting of shareholders.
- Compensation: Ms. Tomasello will receive compensation in accordance with the company's non-employee director policy. No other transactions or arrangements regarding her appointment were disclosed.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of risks and contingencies. It includes a Regulation FD disclosure referencing a press release issued on March 31, 2022, regarding the director appointment.
Key Facts for Investor Verification
- Verify the independence status of the newly appointed director, Shawn Tomasello, per Nasdaq standards.
- Confirm the timeline for John Wilson's retirement and the impact on Board composition prior to the 2022 annual meeting.
- Review the company's non-employee director compensation policy referenced in the 2021 proxy statement (Schedule 14A) to understand the financial implications of the new appointment.
- Note the discrepancy between the requested company name (Kalaris Therapeutics) and the actual registrant (AlloVir, Inc.) in the source text.